Walleye Capital
RXDX

Walleye Capital’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Walleye Capital’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,627
Closed -$96K – 3808
2022
Q3 		$96K Sell
1,627
-191,212
-99% -$8.75M ﹤0.01% 2447
2022
Q2 		$5.44M Buy
192,839
+173,475
+896% +$5.03M 0.15% 153
2022
Q1 		$731K Buy
19,364
+10,792
+126% +$427K 0.02% 797
2021
Q4 		$339K Buy
+8,572
New +$268K 0.01% 1176

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Walleye Capital's RXDX Position: Q4 2022 in Review

Walleye Capital sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2022, closing a stake of 1,627 shares — an estimated $96K sold.

Walleye Capital first reported a position in RXDX in Q4 2021 and held it in 4 quarters. The position peaked at $5.44M in Q2 2022. 221 funds tracked by Wall St. Rank hold RXDX as of Q4 2022.

  • Walleye Capital reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Walleye Capital sold 1,627 Prometheus Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $96K.
  • Walleye Capital first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Walleye Capital's Prometheus Biosciences, Inc. Common Stock position peaked at $5.44M in Q2 2022.
  • 221 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.